--- title: "REGENXBIO (RGNX) news: going concern and offering" url: "https://aibio.space/companies/regenxbio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RGNX going concern and offering news: REGENXBIO starts stock option exchange offer for non-executive employees. REGENXBIO Inc. (NASDAQ: RGNX), United States." --- RGNX REGENXBIO Inc. NASDAQ · United States # REGENXBIO (RGNX) news RGNX going concern and offering news Financings · 2026-07-16 ## [REGENXBIO prices $100 million stock offering at $9.00 a share](https://aibio.space/news/regenxbio-prices-100-million-stock-offering-9-00-share/) REGENXBIO launched a $100 million stock offering on July 16, 2026 at $9.00 a share, below the $11.20 close. Its own preliminary estimate puts cash, cash equivalents and marketable securities at about $105.5 million on June 30, down from $150.5 million on March 31. ## Latest REGENXBIO news 1. 2026-06-03 Mergers [REGENXBIO starts stock option exchange offer for non-executive employees](https://aibio.space/news/regenxbio-starts-stock-option-exchange-offer-non-executive-employees/) REGENXBIO opened an option exchange offer for non-executive employees on June 3, 2026, after stockholders approved it. Stockholders rejected a similar program for executives, and the company's 2025 annual report says the year's $193.9 million net loss and a going-concern doubt sit alongside $240.9 million of cash. 2. 2026-06-03 Mergers [REGENXBIO starts stock option exchange for non-executive employees](https://aibio.space/news/regenxbio-starts-stock-option-exchange-non-executive-employees/) REGENXBIO started a stock option exchange for non-executive employees on June 3, 2026, after stockholders approved it at the May 29 annual meeting. Stockholders rejected a similar exchange for executives, with 21,021,531 votes against to 14,097,815 for. 3. 2026-02-12 Financings [REGENXBIO registers up to $150,000,000 in share sales through Leerink Partners](https://aibio.space/news/regenxbio-registers-up-150-000-000-share-sales-through-leerink/) REGENXBIO filed a prospectus supplement for up to $150 million of at-the-market stock sales through Leerink Partners. The filing warns of substantial doubt about its ability to continue as a going concern. 4. 2025-05-19 Debt Financing [REGENXBIO receives $150 million at closing of royalty bond loan with HealthCare Royalty](https://aibio.space/news/regenxbio-receives-150-million-closing-royalty-bond-loan-healthcare/) A REGENXBIO subsidiary signed a limited recourse royalty bond with an affiliate of HealthCare Royalty Management, repaid only from royalties. The company says the $150 million received at closing extends its cash runway into early 2027. ## REGENXBIO at a glance - **Ticker**: RGNX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $105.5 million ### Related companies - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) NASDAQ: STRO - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) NASDAQ: PHAT - [Immix Biopharma](https://aibio.space/companies/immix-biopharma/) NASDAQ: IMMX - [Lipella Pharmaceuticals](https://aibio.space/companies/lipella-pharmaceuticals/) OTC: LIPO - [Zeo ScientifiX](https://aibio.space/companies/zeo-scientifix/) OTC: ZEOX - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) NASDAQ: OVID ### Also on NASDAQ - [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) MIST - [DEXCOM INC](https://aibio.space/companies/dexcom/) DXCM - [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) KPRX - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) AVLN - [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) HURA ## What REGENXBIO does REGENXBIO Inc. describes itself as a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Its investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform to deliver functional genes that enable the production of therapeutic proteins or antibodies. Its named development partners are AbbVie, which collaborates on surabgene lomparvovec (sura-vec, ABBV-RGX-314), and Nippon Shinyaku Co., Ltd., which collaborates on RGX-121 (clemidsogene lanparvovec) and RGX-111. The text refers to a Complete Response Letter for RGX-121 and to clinical holds on RGX-111 and RGX-121 that must be resolved to the satisfaction of the FDA. The company runs clinical trials under names including AAVIATE, AFFINITY BEYOND, AFFINITY DUCHENNE, ALTITUDE, ASCENT, ATMOSPHERE, CAMPSIITE and NAAVIGATE. Its forward-looking statements name the ability to continue as a going concern and the impact of government-imposed tariffs on partnered product candidates among the factors that could affect results. | Product or program | What it is | Stage | |---|---|---| | sura-vec (ABBV-RGX-314) | Gene therapy in a collaboration with AbbVie | | | RGX-121 (clemidsogene lanparvovec) | Gene therapy in a collaboration with Nippon Shinyaku | Complete Response Letter received; clinical hold | | RGX-111 | Investigational AAV gene therapy in a collaboration with Nippon Shinyaku | clinical hold | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm). ## REGENXBIO annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$228.3 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | [$208.5 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | | Net income (loss) | [-$193.9 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | [-$227.1 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | | Cash from operations | [-$124.0 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | [-$173.1 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | | Cash and equivalents | [$34.5 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336725/) | [$57.5 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | | Short-term investments | [$195.6 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336725/) | [$177.2 million](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $36.5 million, plus short-term investments of $69.0 million, $105.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about REGENXBIO Has REGENXBIO issued a going-concern warning? Our latest story on this, dated Jun 3, 2026: "REGENXBIO starts stock option exchange offer for non-executive employees". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regenxbio-starts-stock-option-exchange-offer-non-executive-employees/). Has REGENXBIO raised money recently? Our latest story on this, dated Jul 16, 2026: "REGENXBIO prices $100 million stock offering at $9.00 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/regenxbio-prices-100-million-stock-offering-9-00-share/). What is the ticker symbol of REGENXBIO? REGENXBIO Inc. trades under the ticker RGNX on NASDAQ. Where is REGENXBIO listed? REGENXBIO Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:RB0; LS:A140E0; LSX:A140E0. What is the SEC CIK of REGENXBIO? The SEC Central Index Key (CIK) for REGENXBIO Inc. is 1590877. Its filings are on SEC EDGAR. How many shares does REGENXBIO have outstanding? 66,013,192 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is REGENXBIO listed under? Our directory records REGENXBIO Inc. under United States. What does REGENXBIO do? Our directory classifies REGENXBIO Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of REGENXBIO? The ISIN recorded for REGENXBIO Inc. is US75901B1070. Does aibio.space cover REGENXBIO? aibio.space lists REGENXBIO Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does REGENXBIO develop? REGENXBIO Inc. describes itself as a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Its investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform to deliver functional genes that enable the production of therapeutic proteins or antibodies. What is sura-vec (ABBV-RGX-314) from REGENXBIO? sura-vec (ABBV-RGX-314): Gene therapy in a collaboration with AbbVie What is RGX-121 (clemidsogene lanparvovec) from REGENXBIO? RGX-121 (clemidsogene lanparvovec): Gene therapy in a collaboration with Nippon Shinyaku Stage: Complete Response Letter received; clinical hold. Is REGENXBIO profitable? REGENXBIO Inc. reported a net loss of $193.9 million for the fiscal year ended Dec 31, 2025, and used $124.0 million of cash in operations, per its annual report to the SEC. How much does REGENXBIO spend on research and development? $228.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: REGENXBIO Members talk about REGENXBIO (RGNX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at REGENXBIO, newest first. Each line links the filing it comes from. 1. 2026-07-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526306170/d133519d424b5.htm) 2. 2026-06-03 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526254590/rgnx-20260529.htm) 3. 2026-06-03 Financings Offered to buy back its own securities. SEC Form SC TO-I. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526254638/rgnx-20260603.htm) 4. 2026-05-14 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526222804/rgnx-20260331.htm) 5. 2026-03-05 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm) 6. 2026-03-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526094013/rgnx-20251231.htm) 7. 2026-02-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312526048688/d94681d424b5.htm) 8. 2024-12-09 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1590877/000119312524273467/d837203dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RGNX on TradingView](https://www.tradingview.com/symbols/NASDAQ-RGNX/). ## SEC filings and registration - **SEC name**: REGENXBIO Inc. - **CIK**: 1590877 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: RGNX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850 - **Phone**: 240-552-8181 - **Shares outstanding**: 66,013,192 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: ReGenX Biosciences, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526423376/rgnx-20261014.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/rgnx-20260923.htm) filed 2026-09-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526365287/rgnx-20260825.htm) filed 2026-08-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526363786/rgnx-20260824.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336725/rgnx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526336716/rgnx-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1590877/000119312526308342/d40931d8k.htm) filed 2026-07-20 - [424B5](https://www.sec.gov/Archives/edgar/data/1590877/000119312526308027/d133519d424b5.htm) filed 2026-07-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001590877), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details REGENXBIO Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RGNX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: REGENXBIO Inc. - **Ticker**: RGNX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US75901B1070 - **Other listed symbols**: GETTEX:RB0; LS:A140E0; LSX:A140E0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RGNX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/regenxbio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "REGENXBIO (RGNX) news: going concern and offering", 2026-10-31, https://aibio.space/companies/regenxbio/